August 15, 2020

The Niche

Knoepfler lab stem cell blog

Search Results for: ocata

1 min read

It’s been a busy few weeks for the stem cell field. Below are some news briefs on developments. RetractionWatch reports that Piero Anversa is leaving Harvard/Brigham and Women’s Hospital after an investigation and dismissed lawsuit he filed against the institution. All still quiet on the STAP cell front at the same institutions. There’s some more clarity and confusion over the Japanese regulatory sphere for IPS cells. New regs may not be issued for another 4 or more months, leaving the clinical studies there in …Read More

1 min read

Astellas Pharma is on track to purchase Ocata Therapeutics (formerly Advanced Cell Technology). This has stirred a lot of strong feelings amongst investors in Ocata. (Update, now almost 5 years later, the Ocata vision program is still not going full steam ahead at its new owner it seems). I’ve also been wondering what exactly is Astellas Pharma? Astellas is a giant compared to Ocata with reportedly $11 billion USD in revenue and $1.3 billion in profit just in the year 2013 alone. While Ocata …Read More

1 min read

I asked Ocata CSO, Bob Lanza, for a comment on the big news of the acquisition of the company by Astellas. Here’s what he had to say: “I can say that this is an exciting time for regenerative medicine.  The merger should greatly accelerate the pace of discovery, and, I hope, lead to treatments for a long list of diseases.” The day after hearing the news, I myself feel a bit more optimistic that Astellas will continue this important work and help patients with …Read More

2 min read

Bombshell news in the stem cell field as Ocata Therapeutics (OCAT; formerly Advanced Cell Technology or ACT) is reportedly to be acquired by Astellas Pharma, Inc. The offer for purchase of OCAT will be $8.50/share or almost $380 million. For more details see this detailed PDF from Astellas. This quote on the deal form Ocata: “Paul Wotton, Ph.D., President and CEO, Ocata said, “I am impressed by the vision and commitment of Astellas and believe that with their global resources behind our regenerative platform, patients …Read More